Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, Techne (TECH) reported revenue of $316.18 million, up 4.2% over the same period last year. EPS came in at $0.56, compared to $0.48 in the year-ago quarter.The reported revenue represents a surprise of +0.30% over the Zacks Consensus Estimate of $315.24 million. With the consensus EPS estimate being $0.51, the EPS surprise was +9.80%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Techne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic Growth: 6% versus 5.2% estimated by three analysts on average. Organic Growth - Diagnostics and Genomics: 2% versus the two-analyst average estimate of 6.2%. Organic Growth - Protein Sciences: 7% compared to the 2.8% average estimate based on two analysts. Net Sales- Intersegment revenue: -$0.74 million versus the two-analyst average estimate of -$0.55 million. The reported number represents a year-over-year change of -3.7%. Net Sales- Protein Sciences: $227.69 million compared to the $224.75 million average estimate based on two analysts. The reported number represents a change of +6.1% year over year. Net Sales- Diagnostics and Genomics: $89.23 million versus the two-analyst average estimate of $92.50 million. The reported number represents a year-over-year change of +2%. View all Key Company Metrics for Techne here>>>Shares of Techne have returned -2.2% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bio-Techne Corp (TECH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks